Research Roundup: What we’re reading this week
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
The recently released annual G-FINDER survey found that total global funding for neglected disease research in 2012 amounted to $3.2 billion, which included an increase of $92.1 million—or 3.2 percent—over 2011 levels. Unfortunately, non-US government funding fell by 12.4 percent in 2012, with 11 governments either cutting or freezing funding. This drop was offset by an increase in US government funding by 6.4 percent from 2011.
After returning from the 8th International Summit of Heads of Medicines Regulatory Agencies in Amsterdam, US Food and Drug Administration (FDA) Commissioner Margaret Hamburg wrote in FDA Voice about the increasing need for international regulatory agencies to work together.
The FDA has granted GHTC member Medicines for Malaria Venture and pharmaceutical company GlaxoSmithKline Breakthrough Therapy designation for tafenoquine, an investigational medicine for the treatment and relapse prevention of Plasmodium vivax malaria.
The Bill & Melinda Gates Foundation has named Susan Desmond-Hellmann, chancellor of the University of California, San Francisco, as its new CEO.
A new article on SciDev.net examines how science is now more influential within the US Agency for International Development than it has been for the last two decades.
Civil society groups are reacting to a set of demonstration projects recently selected by a World Health Organization expert panel to find new ways to fund health research for neglected diseases.